K
20.21
-0.32 (-1.58%)
| Previous Close | 20.54 |
| Open | 20.53 |
| Volume | 528,927 |
| Avg. Volume (3M) | 639,104 |
| Market Cap | 1,468,139,264 |
| Price / Sales | 3.75 |
| Price / Book | 3.68 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2024 |
| Profit Margin | -10.20% |
| Operating Margin (TTM) | -15.75% |
| Diluted EPS (TTM) | -0.600 |
| Quarterly Revenue Growth (YOY) | 46.90% |
| Total Debt/Equity (MRQ) | 2.25% |
| Current Ratio (MRQ) | 3.30 |
| Operating Cash Flow (TTM) | 25.69 M |
| Levered Free Cash Flow (TTM) | 22.57 M |
| Return on Assets (TTM) | -5.15% |
| Return on Equity (TTM) | -9.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Kiniksa Pharmaceuticals, Ltd. | Bearish | Bullish |
AIStockmoo Score
-0.7
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -4.0 |
| Average | -0.70 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 4.03% |
| % Held by Institutions | 89.90% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Citigroup, 97.92%) | Buy |
| Median | 37.00 (83.08%) | |
| Low | 34.00 (Wedbush, 68.23%) | Buy |
| Average | 37.00 (83.08%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 21.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 16 Apr 2025 | 34.00 (68.23%) | Buy | 20.54 |
| Citigroup | 13 Mar 2025 | 40.00 (97.92%) | Buy | 22.16 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Apr 2025 | Announcement | Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 |
| 25 Feb 2025 | Announcement | Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution |
| 25 Feb 2025 | Announcement | Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy |
| 20 Feb 2025 | Announcement | Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |